HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Education
Visit Zacks'
Education section for investing guides and other free resources to make you a better investor.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


AGN: Allergan Inc - Full Company Report Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Full Company Report |  Estimates |  Brokerage Recommendations |  Comparison to Industry |  Insiders |  Brokerage Reports |  Zacks Equity Research   |  Annual Report
ALLERGAN INC (NYSE)
AGN 58.62 -0.03 (-0.05%) Vol.  1,239,540 16:04 ET
Allergan, Inc. is a provider of eye care and specialty pharmaceutical products throughout the world with products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets. Its worldwide consolidated revenues are principally generated by prescription and non-prescription pharmaceutical products in the areas of ophthalmology and skin care, neurotoxins, intraocular lenses and other ophthalmic surgical products, and contact lens care products.

 General Information
ALLERGAN INC
2525 Dupont Drive
Irvine, CA 92612
Phone: 714 246-4500
Fax: 714 246-4971
Web: www.allergan.com
Email: None
 
Industry MED-DRUGS
Sector: Medical
 
Fiscal Year End December
Last Reported Quarter 09/30/09
Next EPS Date 02/10/2010
 
 Price and Volume Information
Zacks Rank
Yesterday's Close 58.65
52 Week High 60.85
52 Week Low 32.00
Beta 0.99
20 Day Moving Average 2,048,472.25
Target Price Consensus 64.46
 
 % Price Change
4 Week 3.33
12 Week 6.39
YTD 45.39
 % Price Change Relative to S&P 500
4 Week 2.22
12 Week 0.30
YTD 20.33
 Share Information
Shares Outstanding (millions) 304.06
Market Capitalization (millions) 17,824.00
Short Ratio 2.27
Last Split Date 06/25/2007
 Dividend Information
Dividend Yield 0.34%
Annual Dividend $0.20
Payout Ratio 0.07
Change in Payout Ratio -0.03
Last Dividend Payout / Amount 11/05/2009 / $0.05

 EPS Information
Current Quarter EPS Consensus Estimate 0.77
Current Year EPS Consensus Estimate 2.77
Estimated Long-Term EPS Growth Rate 15.10
Next EPS Report Date 02/10/2010
 Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell) 1.73
30 Days Ago 1.73
60 Days Ago 1.79
90 Days Ago 1.79

 Fundamental Ratios
 P/E
Current FY Estimate: 21.20
Trailing 12 Months: 21.24
PEG Ratio 1.40
 EPS Growth
vs. Previous Year 7.69%
vs. Previous Quarter -6.67%
 Sales Growth
vs. Previous Year 3.92%
vs. Previous Quarter: 0.93%
 Price Ratios
Price/Book 3.90
Price/Cash Flow 16.92
Price / Sales 4.11
 ROE
09/30/09 19.70
06/30/09 20.02
03/31/09 19.67
 ROA
09/30/09 12.16
06/30/09 12.21
03/31/09 11.81
 Current Ratio
09/30/09 3.73
06/30/09 3.71
03/31/09 3.64
 Quick Ratio
09/30/09 3.43
06/30/09 3.37
03/31/09 3.23
 Operating Margin
09/30/09 19.41
06/30/09 19.25
03/31/09 18.26
 Net Margin
09/30/09 17.27
06/30/09 17.61
03/31/09 16.04
 Pre-Tax Margin
09/30/09 17.27
06/30/09 17.61
03/31/09 16.04
 Book Value
09/30/09 15.02
06/30/09 14.28
03/31/09 13.65
 Inventory Turnover
09/30/09 3.06
06/30/09 2.96
03/31/09 2.86
 Debt-to-Equity
09/30/09 0.33
06/30/09 0.34
03/31/09 0.36
 Debt to Capital
09/30/09 24.63
06/30/09 25.40
03/31/09 26.39

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research